A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events
Phase of Trial: Phase IV
Latest Information Update: 27 May 2016
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
- Indications Thromboembolism
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 May 2016 Status changed from active, no longer recruiting to completed.
- 03 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.